We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Drugmakers Comment on FDA’s Guidance on Natural Histories for Rare Diseases
Drugmakers Comment on FDA’s Guidance on Natural Histories for Rare Diseases
Ionis, Merck and Lundbeck offered feedback on the FDA’s guidance for developing natural history studies for rare disease drug development, praising some parts of the guidance but calling for more details.